Pharmacokinetics of Selective Estrogen Receptor Modulators

被引：0
作者：
Karla C. Morello
Gregory T. Wurz
Michael W. DeGregorio
机构：
[1] University of California,Department of Internal Medicine, Division of Hematology/Oncology
[2] Cancer Center,undefined
来源：
Clinical Pharmacokinetics | 2003年 / 42卷
关键词：
Estrogen Receptor; Warfarin; Tamoxifen; Raloxifene; Letrozole;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Selective estrogen receptor modulators (SERMs) are a class of compounds used to treat and prevent breast cancer and osteoporosis. SERMs currently approved for use in patients include tamoxifen, toremifene and raloxifene. These compounds are well tolerated in patients, and the most common adverse effects experienced in patients undergoing SERM therapy include vasomotor symptoms such as hot flashes and vaginal discharge. New SERMs currently under development for use in the treatment and prevention of osteoporosis and breast cancer include ospemifene, a derivative of toremifene, and arzoxifene, a compound very similar in structure to raloxifene.
引用
收藏
页码：361 / 372
页数：11
相关论文
共 195 条
[1]  
Snyder K.R.(2000)Raloxifene hydrochloride Am J Health Syst Pharm 57 1669-78
[2]  
Sparano N.(2001)In vitro and in vivo biologic effects of ospemifene (FC-1270a) in breast cancer J Steroid Biochem Mol Biol 77 271-9
[3]  
Malinowski J.M.(1999)Postmenopausal hormone therapy, SERMs, and coronary heart disease in women J Endocrinol Invest 22 616-24
[4]  
Taras T.L.(2000)Clinical pharmacokinetics of toremifene Clin Pharmacokinet 39 327-34
[5]  
Wurz G.T.(1998)Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients J Clin Endocrinol Metab 83 1158-62
[6]  
DeGregorio M.W.(2000)Selective estrogenic effects of a novel triphenylethylene compound, PC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats Endocrinology 141 809-20
[7]  
Wenger N.K.(1998)LY353381.HCl: a novel raloxifene analog with improved SERM potency and efficacy in vivo J Pharmacol Exp Ther 287 1-7
[8]  
Grady D.(1996)Pharmacokinetics and bioavailability of tamoxifen in postmenopausal healthy women Arzneimittel Forschung 46 418-22
[9]  
Taras T.L.(1998)Tamoxifen and toremifene in breast cancer: comparison of safety and efficacy J Clin Oncol 16 348-53
[10]  
Wurz G.T.(1998)Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study J Natl Cancer Inst 90 1371-88
12345678910